Inovio Pharma to develop Ebola treatment backed by Defense Advanced Research Projects Agency
Thursday, April 09, 2015
The Defense Advanced Research Projects Agency (DARPA) awards a two-year $21M grant to a collaborative team led by Inovio Pharmaceuticals (NASDAQ:INO) to develop multiple treatment and prevention regimens against Ebola. Other members include GeneOne Life Sciences, MedImmune (NYSE:AZN), Professor David B. Weiner, Ph.D. (University of Pennsylvania), Emory University and Vanderbilt University.
Development programs include a therapeutic DNA-based monoclonal antibody (dMab) and a protein-based therapeutic monoclonal antibody (mAb) against Ebola infection and Inovio's DNA-based Ebola vaccine (the first patient is expected to be dosed this quarter).
The grant includes an option award of $24M and an additional option of $11M to support product supply and clinical development activities. Both options are contingent on the successful completion of certain development milestones.
seekingalpha.com
